Background {#Sec1}
==========

Under the auspices of the US Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO), and the University of Geneva Hospitals and Faculty of Medicine (HUG), an international panel of 42 experts with backgrounds in infection prevention and control (IPC), microbiology, infectious diseases, public health, psychology, medical technology, and social sciences, convened for 2 days at the Geneva Think Tank on IPC and antimicrobial resistance (AMR) in June 2017. The aim was to develop a global vision on IPC and AMR, and to agree on a road map for research and public health activities. Three dimensions of IPC and AMR were discussed: 1) implementation of IPC and antimicrobial stewardship; 2) technology in IPC and AMR; and 3) broadening the global IPC network. This is the final paper in a series of three summarising the discussions during the meeting, and addressing the current and future role of networks in IPC.

Methods {#Sec2}
=======

Two key areas for strengthening the IPC networks globally were addressed: 1) broadening collaboration among IPC organisations around the world; and 2) improving and aligning IPC and AMR control efforts. Two impulse talks for each of the areas set the stage for a moderated plenary discussion. Writers took notes. This paper is the summary of presentations and notes taken from the plenary discussion.

Results {#Sec3}
=======

CDC, the European Centre for Disease Prevention and Control (ECDC), and the WHO convened together and with international experts to exchange their visions about collaboration and networking, and demonstrated their commitment for close collaboration in IPC.

Broadening the collaboration in infection prevention and control and antimicrobial resistance {#Sec4}
---------------------------------------------------------------------------------------------

A number of international IPC and AMR networks are already in place (Table [1](#Tab1){ref-type="table"}). The WHO Global IPC Network brings together major international and national IPC organisations and in 2017, issued a call to action related to the global and national IPC priorities for 2018--2022 \[[@CR1]\]. Pre-existing surveillance modules on AMR, antimicrobial consumption, and HAI surveillance in Europe have been integrated to become the ECDC ARHAI-Net (Antimicrobial resistance and healthcare-associated infection network). This network collaborates with a number of other networks. The Trans-Atlantic Task Force for Antimicrobial Resistance (TATFAR) is an example of a transatlantic collaboration between a number of European and US members (Table [1](#Tab1){ref-type="table"}). The initiative agreed on 17 recommendations in 3 key areas: appropriate therapeutic use of antimicrobial drugs in medical and veterinary communities; prevention of drug-resistant infections; strategies for improving the pipeline of new antimicrobial drugs and diagnostic devices, and maintaining existing drugs on the market. There was consensus in the group that the natural stakeholders for international collaboration are CDC, ECDC, and WHO, although other regional or global organisations should also be engaged. These public health organisations work on the political level, cascading ideas and policies down to ministries of health.Table 1Collaborative networks in infection prevention and control and antimicrobial resistance on national and international levelsAcronymNetworkLeadDescription/MissionLinksARHAI-NetAntimicrobial Resistance and Healthcare-Associated Infections NetworkECDCFocus on surveillance, scientific advice, training and communication to address the threat of antimicrobial resistance and healthcare-associated infections.\
ARHAI integrated the former European programmes ESAC on antimicrobial consumption, EARSS on antimicrobial resistance, HELICS on healthcare-associated infections (surgical site infections; HAI in intensive care), and IPSE on a wider patient safety context.<https://ecdc.europa.eu/en/about-us/who-we-are/disease-programmes/antimicrobial-resistance-and-healthcare-associated>EIPEmerging Infections ProgramUS-CDCPrevention and control of infectious diseases by providing scientific information to monitor emergency problems, evaluate public health interventions, and inform policy.<https://www.cdc.gov/ncezid/dpei/eip/index.html>IMIInnovative Medicines InitiativeEC & EFPIAWorking group on accelerating development and access to innovative medicines, particularly in areas where there is an unmet need.\
IMI is the world's biggest public-private partnership in life sciences.<https://www.imi.europa.eu/about-imi/mission-objectives>GIPCNGlobal Infection Prevention and Control NetworkWHOGIPCN aims to enhance local, national and international coordination and collaboration in the field of IPC and to support WHO's and countries' efforts on IPC, from preparedness, to IPC systems and programmes' strengthening, outbreak prevention and control, as well as capacity building for surveillance.<http://www.who.int/infection-prevention/about/GIPC_Network/en/>GLASSGlobal Antimicrobial Resistance Surveillance SystemWHOGLASS promotes and supports a standardized approach to the collection, analysis and sharing of AMR data at a global level by encouraging and facilitating the establishment of national AMR surveillance systems that are capable of monitoring AMR trends and producing reliable and comparable data.<https://www.who.int/glass/partnerships/en/>JPIAMRJoint Programming Initiative on Antimicrobial ResistanceEUBasic and exploratory research on new antibiotics, stewardship of existing antibiotics, and control of the spread of antibiotic resistance between humans, animals, and the environment in a One Health perspective (26 countries globally).<https://www.jpiamr.eu/>POPSPrivate Organizations for Patient SafetyWHOPublic-private partnership to harness industry strengths to align and improve implementation of WHO recommendations in different parts of the world.<http://www.who.int/infection-prevention/about/pops/en/>TATFARTrans-Atlantic Force for Antimicrobial ResistanceUS-CDCTransatlantic collaboration between US-CDC, ECDC, EC, EFSA, FDA, AMA, OGHA, and USDHS.\
Improving appropriate therapeutic use of antimicrobial drugs in medical and veterinary communities; preventing healthcare- and community-associated drug-resistant infections, and developing strategies for improving the pipeline of new antimicrobial drugs.<https://www.cdc.gov/drugresistance/tatfar/index.html>Antibiotic Resistance Solutions InitiativeUS-CDCThe initiative invests in national infrastructure to detect, respond, contain, and prevent resistant infections across healthcare settings, food, and communities. CDC funding supports all 50 state health departments, six local health departments, and Puerto Rico.<https://www.cdc.gov/drugresistance/solutions-initiative/index.html>Prevention EpiCentersUS-CDCCollaborative research programme between the CDC's division of healthcare quality promotion and academic investigators for conducting innovative infection prevention and control research.<https://www.cdc.gov/hai/epicenters/index.html>WHO *SAVE LIVES: Clean Your Hands*WHOWHO's global annual campaign making a call to action for health workers every 5 May concerning preventing HAI through hand hygiene and IPC improvements .<http://www.who.int/infection-prevention/campaigns/clean-hands/en/>*AMA* American Medical Association, *EARSS* European Antimicrobial Resistance Surveillance System, *EC* European Commission, *EFPIA* European Federation of Pharmaceutical Industries and Associations, *EFSA* European Food Safety Authority, *ESAC* European Surveillance on Antimicrobial Consumption, *EU* European Union, *FDA* US Food and Drug Association, *HAI* Healthcare-associated infection, *HELICS* Hospitals in Europe Link for Infection Control through Surveillance, *IPSE* Improving Patient Safety in Europe, *NIH* US National Institutes of Health, *OGHA* Office of Global Health Affairs, *US-CDC* US Centers for Disease Control and Prevention, *USDHS* US Department of Homeland Security, *WHO* World Health Organization

Experts in IPC and professional societies may not have a public health perspective, but the role they play in driving innovation and generating ideas and solutions cannot be dismissed given the impact of such efforts on future public health decision making. Ideally, expert-to-expert collaboration would include international public health bodies. Any resulting innovations would be more likely to incorporate global or higher-level policy perspectives, with the potential impact extending beyond research to become standard in patient care. The WHO *SAVE LIVES: Clean Your Hands* campaign exemplifies the success of such collaboration, where the campaign principle is that public health and IPC experts work hand-in-hand to drive improvement \[[@CR2]\]. In addition, the WHO hand hygiene campaign benefits from the collaboration of a public-private partnership, developed under the umbrella of the WHO Private Organizations for Patient Safety (POPS)-Hand Hygiene. This collaboration, among others, enables campaign messaging to be spread at the bedside in many countries, using multiple languages, and adapting to different cultural and resource needs \[[@CR2]\]. Through its collaborating centres, WHO has further strengthened the network between public health and academic institutions. The integration of Improving Patient Safety in Europe (IPSE), European Surveillance of Antimicrobial Consumption (ESAC), and European Antimicrobial Resistance Surveillance System (EARSS) under the umbrella of ECDC's ARHAI-Net is another example of successfully transforming academic work into a large scale public health initiative. Examples from CDC's numerous collaborations with academia include the Prevention EpiCenters and the Emerging Infections Program (EIP). There is little collaboration of the many private initiatives in IPC and AMR. As partners, international organisations can streamline and leverage the effect of such activities.

A challenge is the fact that research, and consequently the guidance based on scientific findings, is typically generated in high income countries. More research in low-and-middle-income countries (LMICs) is needed, but until this is available, at a minimum, the applicability of recommendations to LMIC contexts should be assessed. The WHO core components for IPC are a good example of guidelines based on data primarily from high income settings that have been integrated with experience and additional evidence from the field gathered in LMIC settings according to a solid methodology. In collaboration with CDC, WHO has developed implementation tools with special focus on low resource settings, to support the adaptation and adoption of the guidelines into the local context \[[@CR3], [@CR4]\]. These are examples on how international organisations can fill their role as trusted promoters in improving the implementation of IPC and AMR control in LMIC.

How to bring IPC and antimicrobial resistance control together {#Sec5}
--------------------------------------------------------------

Emerging AMR is a global problem, which can only be controlled if stakeholders are working together at an international level. AMR control relies on four pillars: 1) surveillance (of infections, resistance and antimicrobial use); 2) IPC (prevention of AMR transmission); 3) antimicrobial stewardship; and 4) research and development. It is well accepted that all four pillars are needed to both define the problem (research, surveillance), and to solve it (IPC, antimicrobial stewardship).

Preventing the spread of multidrug-resistant organisms depends predominantly on good IPC practice in healthcare facilities, particularly hand hygiene, institutional environmental cleaning, and isolation precaution measures. Prevention of spread in the community setting is also predicated on the existence of adequate water, sanitation and hygiene measures. Additional measures include screening of patients at risk for carriage of multi-resistant organisms according to defined strategies that are adapted to individual types of AMR-pathogen combinations. There is sufficient evidence that such strategies work, the recommended actions are straight-forward, and they can be applied immediately. If cross-transmission is not contained, other AMR strategies such as antimicrobial stewardship or the development of new antimicrobials will be very limited in both effect and sustained impact.

IPC as a core prevention measure has neither been sufficiently recognized nor prioritized at the global level to adequately address the scope of the AMR problem. The field of IPC is not adequately interconnected with the AMR community. This dichotomy is rooted in history. Research in AMR is infectious diseases and microbiology-driven, often focusing on resistance mechanisms and genetic relatedness. Infection prevention and control has a more practical attitude focusing on the prevention of cross-transmission by promoting best practice procedures. Scope and professional backgrounds of stakeholders in IPC and AMR are often different. However, the need for collaboration between the two has become more urgent. International organisations such as CDC, ECDC, and WHO could take a lead on bridging the gap between IPC and AMR experts. ECDCs ARHAI network and CDC's Antibiotic Resistance Solutions Initiative are examples where activities on AMR and IPC are under the same umbrella.

Discussion {#Sec6}
==========

International organisations should take the lead in both strengthening existing and creating new networks, which will attract academia and other stakeholders to join. At the same time, they should invest in bringing existing IPC and AMR networks under one umbrella. Transmission of multidrug-resistant microorganisms in hospitals and in the community threatens successful combating of AMR, and thus, measures to interrupt transmission i.e. effective IPC strategies and programmes supported by effective international and national networks should be given more priority globally.

Conclusion {#Sec7}
==========

The working group determined that international organisations should take the lead in creating new networks, and invest in bringing existing IPC and AMR networks under one umbrella. Research and development in IPC should be addressed as an enhanced global priority.
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